At clinical level, SAHA monotherapy demonstrates tolerable toxicity, but its therapeutic response remains limited, indicating that combination therapy with other agents may offer more substantial benefits; combined therapy with tamoxifen has shown, for example, promising anti-tumor effects in ER+ BC patients with advanced disease [185]. The gene discussed is ESR1; the disease is breast cancer.